Company / Cash & Equivalents
Disc Medicine, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$91.1M
FY2025
5-year range
$88.0M / $360.4M
FY2021-FY2025
Trend
-52.6%
vs FY2024
Sector context
#146 of 207
Health Care
What the data says
At $91M, Disc Medicine, Inc.'s cash & equivalents ranks #146 of 207 in the Health Care sector. Declined from $360M to $91M over the past 2 years.
Based on SEC 10-K filings.
$91M in FY2025 with a 5-year CAGR of +82.5%.
Declined from $360M to $91M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -22.3%
- 5-Year CAGR
- +82.5%
- 10-Year CAGR
- -
Sector benchmark
#146 of 207 in Health CareTop 71% of 207This company $91.1M Sector average $669.5M
▼
-86.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +82.5%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 52.6% year-over-year.
- Ranks #146 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 4.41 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $91.1M | -52.6% |
| FY2024 | $192.4M | -46.6% |
| FY2023 | $360.4M | +85.2% |
| FY2022 | $194.6M | +121.1% |
| FY2021 | $88.0M | +1855.1% |
| FY2020 | $4.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026